ASAdriana Martins de Sousa

Adriana Martins de Sousa

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Adriana Martins de Sousa has a total of 34 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Improvement in Outcomes of Childhood Acute Myeloid Leukemia Treatment: A Survival Analysis at a Reference University Hospital in Rio de Janeiro, Brazil

    by Thais Alcantara Bonilha, Deborah Sutter Ayres Pereira, Alice Maria Boulhosa de Azevedo, Adriana Martins de Sousa, Elaine Sobral da Costa, Marcelo Gerardin Poirot Land

    Background: Acute myeloid leukemia (AML) represents 15% to 20% of all pediatric acute leukemias and is responsible for nearly 30% of deaths in this population. While high‐income countries report overall survival (OS) rates near 75%, survival in Brazil remains significantly lower, ranging between 30% and 40%. Aims: The objective of this study is to analyze the probability of OS and event‐free survival (EFS) in pediatric patients with AML treated at a Brazilian university hospital, evaluate prognostic factors, and compare outcomes with international data. Methods and Results: This retrospective study included 51 patients (under 14 years old) diagnosed between 2004 and 2023 and treated with BFM‐based protocols. The median age was 4.6 years. Patients with acute promyelocytic leukemia (APL) achieved an OS of 100% and EFS of 90%. For other AML subtypes, the 5‐year OS and EFS were 53.7% and 43.7%, respectively. Implementation of improved supportive care (ISC) after 2008—including the opening of a pediatric ICU and better infection management—was a pivotal prognostic factor ( p < 0.001). Following ISC implementation, OS increased dramatically from 8.3% to 74.5%, and the early death rate dropped to 5.7%, reaching levels comparable to high‐income countries. Conclusions: Pediatric AML outcomes in developing regions can achieve international standards when intensive chemotherapy is combined with optimized supportive care. The establishment of specialized pediatric intensive care and advanced management of infectious complications are essential pillars for bridging the survival gap in these populations.

  • Open Access

    Management of pediatric acute leukemias relapse after hematopoietic cell transplantation

    by Rita de Cássia Barbosa Tavares, Polliany Roberta Dorini Pelegrina, Carla Nolasco Monteiro Breviglieri, Ana Luiza de Mello Rodrigues, Gustavo Zamperlini, Adriana Martins de Sousa, Patricia Regina Cavalcanti Barbosa Horn, Luiz Guilherme Darrigo Jr, Liane Daudt

    Prevention is the best way to avoid relapse after hematopoietic cell transplantation (HCT). Immunomodulation can enhance graft-versus-leukemia effect and, if graft-versus-host disease (GVHD) is absent, prophylactic donor lymphocyte infusion (DLI) may be indicated for high-risk patients. Maintenance strategies with blinatumomab, inotuzumab, tyrosine kinase inhibitors, hypomethylating agents or venetoclax can be effective in reducing relapse rates. However, maintenance therapy response depends on individual toxicity and physician’s experience in handle with dose adjustments, undesirable drug interactions and complications. Preemptive approach guided by minimal residual disease (MRD) or mixed chimerism is fundamental to prevent hematologic relapse. Target agent or immunotherapy followed by DLI can be used, and if no response, low-dose chemotherapy can be added to reach disease control. After relapse, antigen-directed therapies with blinatumumab for CD19 ALL and inotuzumab for CD22 ALL are good options to induce MRD negativity and bridge to second HCT. Emerging therapies like daratumumab, immune checkpoint or menin inhibitors are promising but require validation. CAR-T cell therapy can provide a better chance of long-term survival if low leukemia burden and absence of GVHD. It is also effective in extramedullary disease, mainly in central nervous system relapse. Patients with B-cell aplasia loss after CAR T-cell therapy are second transplant candidates, as well as those with acute myeloid leukemia who respond to salvage therapy. Second HCT outcomes are better if relapse occurred ≥ 12 months after the first HCT. Strategies for expanding access to immunotherapy and target agents are crucial to improve long-term survival in these children.


  • Open Access

    Sickle cell disease

    by Luiz Guilherme Darrigo Junior, Roseane Vasconcelos Gouveia, Cilmara Kuwahara, Alexandre de Albuquerque Antunes, Adriana Martins de Sousa, Ana Karine Vieira, Ainá Henriques Melgaço, Juliana Folloni Fernandes, Adriana Seber

    Sickle cell disease (SCD) is known as the most common hemoglobin disorder, with severe forms of thalassemia syndromes following closely. Current standard treatments, including transfusions, hydroxyurea, and L-glutamine, still do not significantly improve life expectancy and quality of life for patients. Allogeneic hematopoietic cell transplantation (HCT) remains the only curative option, showing overall survival and event-free survival rates over 90%, especially in patients under 16 years old. However, only 15% of SCD patients have access to an unaffected family donor. To increase donor availability, alternative sources such as matched unrelated donors, unrelated umbilical cord blood, and haploidentical donors have become viable options for patients without a matched related donor. The aim of this article was to update the Brazilian consensus previously published by the Brazilian Society of Cellular Therapy and Bone Marrow Transplantation in 2021, highlighting the latest developments in the treatment and monitoring of patients with SCD undergoing HCT.

  • Open Access

    Hematopoietic cell transplantation in inherited bone marrow failure syndromes

    by Gisele Loth, Luiz Guilherme Darrigo Júnior, Adriana Martins de Sousa, Alexandre de Albuquerque Antunes, Ana Karine Vieira

    Inherited bone marrow failure syndromes (IBMFS) comprise a heterogeneous group of rare genetic disorders characterized by defective hematopoiesis, congenital anomalies, and a predisposition to clonal evolution and malignancies. Hematopoietic cell transplantation remains the only curative option for the hematologic manifestations of these disorders, although it does not correct congenital malformations or eliminate the long-term risk of non-hematopoietic cancers. This review summarized current evidence and transplantation strategies for major IBMFS, including Fanconi anemia, dyskeratosis congenita/telomere biology disorders, Diamond-Blackfan anemia, Shwachman-Diamond syndrome, congenital neutropenia, congenital amegakaryocytic thrombocytopenia, and other inherited thrombocytopenias. We discussed disease-specific transplant indications, donor selection, conditioning regimens, graft source preferences, and outcomes across different patient populations. Advances in reduced-intensity conditioning and post-transplant cyclophosphamide have expanded donor availability, improving survival even with alternative donors. Nevertheless, long-term challenges persist, such as increased risks of solid tumors, endocrine dysfunction, and organ toxicity, emphasizing the need for multidisciplinary care and lifelong surveillance. Optimal outcomes depend on timely referral to specialized centers, meticulous donor screening, and individualized transplant strategies tailored to the unique biology of each disorder.

  • Open Access

    Donor leucocyte infusion

    by Adriana Martins de Sousa, Rita de Cassia Barbosa Tavares, Gil Cunha De Santis, Adriana Seber

    Donor-derived cellular therapies play a pivotal role in optimizing outcomes after allogeneic hematopoietic stem-cell transplantation (HCT). This article reviews three key post-transplant interventions: donor lymphocyte infusion (DLI), hematopoietic stem-cell boost, and mesenchymal stromal cell (MSC) infusion. DLI remains a cornerstone strategy for enhancing graft-versus-leukemia effects, preventing or treating relapse, and promoting immune reconstitution, while also carrying risk of graft-versus-host disease. Stem-cell boosts, typically performed using CD34⁺ selected products, offer an effective approach for managing poor graft function or mixed chimerism without significantly increasing alloimmune toxicity. MSC infusion has emerged as a promising immunomodulatory therapy for steroidrefractory graft-versus-host disease and for facilitating engraftment, owing to its anti-inflammatory and tissueregenerative properties.

  • Open Access

    Hematopoietic stem cell transplantation for pediatric acute myeloid leukemia

    by Ana Luiza de Melo Rodrigues, Adriana Seber, Luciana Domingues, Victor Gottardello Zecchin, Maria Lúcia de Martino Lee, Liane Daudt, Luiza de Souza, Adriana Martins de Sousa, Antonella Adriana Zanette, Carla Nolasco, et al.

    Acute myeloid leukemia (AML) accounts for 15% to 20% of pediatric acute leukemia cases. Treatment failure is influenced by both genetic risk and response to therapy1,2,3,4. Although the initial remission rate exceeds 90%, more than 30-40% of children with AML die of refractory/relapsed disease or treatment-related toxicity5. Improved survival outcomes are associated with comprehensive strategies that combine intensive chemotherapy, effective supportive care, and hematopoietic stem cell transplantation (HCT), adjusted to the relapse risk profile of each patient6-10. In 2020, the Brazilian Group for Pediatric Bone Marrow Transplantation of the Brazilian Society of Bone Marrow Transplantation and Cellular Therapy (SBTMO) and the Brazilian Society for Pediatric Oncology (SOBOPE) convened a task force to provide general guidance on HSCT for childhood AML, to provide evidence-based guidance for the appropriate management of this disease. This is the 2025 update of the previously guideline.